AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24626137 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral water immersion (TNI; 34 ± 0.5° C)
Number of subjects: 7
Study 22613412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l) for 3 months prior to surgery
Number of subjects: 49
Study 22613412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide treatment
Number of subjects: 49
Study 22613412 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-sphenoidal surgery after lanreotide treatment
Number of subjects: 49
Study 22613412 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 49
Study 20107463 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND Program (intervention group)
Number of subjects: 116
Study 20107463 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (control group)
Number of subjects: 116
Study 17980395 — intervention group
Group type: EXPERIMENTAL
Intervention: High selenium levels
Number of subjects: 172
Study 17980395 — intervention group
Group type: COMPARATOR
Intervention: Low selenium levels
Number of subjects: 172
Study 15892286 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene plus Yijing Huoxue Cuyun Decoction (YHCD)
Number of subjects: 118
Study 15892286 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene plus YHCD
Number of subjects: 118
Study 15892286 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene plus estradiol valerate
Number of subjects: 118
Study 12645445 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CI)
Number of subjects: 0
Study 12645445 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study 10807025 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intensity for the last year and month of life for deceased clients
Number of subjects: 278
Study 10807025 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment intensity for all clients
Number of subjects: 278
Study 10807025 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intensity in the last month of life for all age groups
Number of subjects: 278
Study 8858555 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage instructions and content (alcoholic vs non-alcoholic beer)
Number of subjects: 132
Study 8858555 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 132
Study 1644012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 48
Study 1644012 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 48
Study 6324526 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation therapy (mild treatment with panretinal, focal or both techniques using short‐pulse, small‐spot xenon arc or argon laser methods)
Number of subjects: 211
Study 6324526 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (not treated with photocoagulation)
Number of subjects: 211
Study 6324526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild non‐proliferative changes
Number of subjects: 211
Study 6324526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate-severe non‐proliferative changes
Number of subjects: 211
Study 31654891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mug
Number of subjects: 1059
Study 31654891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5mug
Number of subjects: 1059
Study 31654891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 29986507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy logic-based estimation mechanism for IoT service quality
Number of subjects: 0
Study 29986507 — intervention group
Group type: COMPARATOR
Intervention: Randomization Test (RT)
Number of subjects: 0
Study 29986507 — intervention group
Group type: COMPARATOR
Intervention: Single Test in Steps (STS)
Number of subjects: 0
Study 26812052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg per day
Number of subjects: 326
Study 26812052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 26812052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg per day (females)
Number of subjects: 326
Study 26812052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (females)
Number of subjects: 326
Study 24445121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied heat at 42°C for 30 seconds daily with allantoin lotion formulation
Number of subjects: 0
Study 24445121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied heat at 42°C for 30 seconds daily with allantoin gel formulation
Number of subjects: 0
Study 24445121 — intervention group
Group type: COMPARATOR
Intervention: Control site with no active and no heat
Number of subjects: 0
Study 23229961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐initiated adherence support by pharmacists following computer‐generated missed refill alerts.
Number of subjects: 265
Study 23229961 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 265
Study 20795810 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized materials
Number of subjects: 0
Study 20795810 — intervention group
Group type: COMPARATOR
Intervention: Non-personalized materials
Number of subjects: 0
Study 17337493 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 315
Study 17337493 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin injection
Number of subjects: 315
Study 15721015 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (400 mg daily for 4 weeks)
Number of subjects: 97
Study 15721015 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide treatment (Roxithromycin)
Number of subjects: 97
Study 15721015 — intervention group
Group type: COMPARATOR
Intervention: Seropositive untreated group
Number of subjects: 97
Study 15721015 — intervention group
Group type: COMPARATOR
Intervention: Seronegative and macrolide-treated group
Number of subjects: 97
Study 15721015 — intervention group
Group type: COMPARATOR
Intervention: C. pneumoniae seropositivity
Number of subjects: 97
Study 15721015 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Number of subjects: 97
Study 11574432 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 27
Study 11574432 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injection (MDI)
Number of subjects: 27
Study 11574432 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 27
Study 11574432 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 27
Study 9780764 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3% inspired concentration)
Number of subjects: 98
Study 9780764 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.5% inspired concentration)
Number of subjects: 98
Study 8092865 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 14
Study 8092865 — intervention group
Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 14
Study 3103424 — intervention group
Group type: EXPERIMENTAL
Intervention: Red pepper (0.1-1.5 g)
Number of subjects: 0
Study 3103424 — intervention group
Group type: EXPERIMENTAL
Intervention: Black pepper (1.5 g)
Number of subjects: 0
Study 3103424 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (655 mg)
Number of subjects: 0
Study 3103424 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study 31757568 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 0
Study 31757568 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 30253174 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg
Number of subjects: 16
Study 30253174 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg
Number of subjects: 16
Study 30253174 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study 27448942 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Chloride (KCl) for 4 weeks
Number of subjects: 0
Study 27448942 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Magnesium Citrate (KMgCit)
Number of subjects: 0
Study 27448942 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Citrate (KCit)
Number of subjects: 0
Study 27448942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24602708 — intervention group
Group type: EXPERIMENTAL
Intervention: Short laparoscopic training session
Number of subjects: 205
Study 24602708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 205
Study 24602708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 205
Study 23347808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.1μg/kg/min for 10 minutes prior to induction and 0.7μg/kg/hour until 10 minutes before the end of the operation.
Number of subjects: 60
Study 23347808 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group).
Number of subjects: 60
Study 21643719 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to multiple competing stimulus items
Number of subjects: 0
Study 21643719 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous presentation of multiple items
Number of subjects: 0
Study 21643719 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to single items
Number of subjects: 0
Study 21643719 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional status of items
Number of subjects: 0
Study 18372428 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days
Number of subjects: 12
Study 16490976 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) applied before skin closure
Number of subjects: 107
Study 16490976 — intervention group
Group type: COMPARATOR
Intervention: No Povidone-iodine (control group)
Number of subjects: 107
Study 12943960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30-60 mg/daily) in addition to cognitive-behavioral detoxification protocol
Number of subjects: 54
Study 12943960 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral detoxification protocol (non-pharmacological approach)
Number of subjects: 54
Study 10843747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous catheter
Number of subjects: 20
Study 10843747 — intervention group
Group type: COMPARATOR
Intervention: Needle stick (control)
Number of subjects: 20
Study 9150698 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms C-type natriuretic peptide
Number of subjects: 8
Study 9150698 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms C-type natriuretic peptide
Number of subjects: 8
Study 9150698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8468438 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg three times daily)
Number of subjects: 345
Study 8468438 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin (75 mg daily for first two weeks, then 150 mg thereafter)
Number of subjects: 345
Study 8468438 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin (75-150 mg)
Number of subjects: 345
Study 8468438 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg)
Number of subjects: 345
Study 8468438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 345
Study 6222700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroids (Triamcinolone acetonide at 0.63 mg/mL)
Number of subjects: 0
Study 6222700 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroids (Betamethasone phosphate at 3.0, 1.5, and 0.75 mg/mL)
Number of subjects: 0
Study 30932903 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (M1‐SO montage, anode ipsilesional, 5×7 cm electrodes, 2 mA, 20 mins) prior to robotic upper‐limb training (12 weeks; 36 sessions)
Number of subjects: 82
Study 30932903 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS prior to robotic upper‐limb training (12 weeks; 36 sessions)
Number of subjects: 82
Study 30932903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tDCS and sham)
Number of subjects: 82
Study 29731416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 0
Study 29731416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced increases in IL-6
Number of subjects: 0
Study 29731416 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 inhibition
Number of subjects: 0
Study 27553622 — intervention group
Group type: EXPERIMENTAL
Intervention: EmbryoScope™
Number of subjects: 48
Study 27553622 — intervention group
Group type: COMPARATOR
Intervention: Standard embryology
Number of subjects: 48
Study 25657364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (supervised hands-on education, peer assessment/education, and simulated scenario counseling real asthma patients)
Number of subjects: 109
Study 25657364 — intervention group
Group type: COMPARATOR
Intervention: Intervention A (supervised hands-on education and peer assessment/education)
Number of subjects: 109
Study 22954893 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2496
Study 22954893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2496
Study 19446324 — intervention group
Group type: EXPERIMENTAL
Intervention: Early exercise and mobilisation (physical and occupational therapy) during periods of daily interruption of sedation
Number of subjects: 104
Study 19446324 — intervention group
Group type: COMPARATOR
Intervention: Daily interruption of sedation with therapy as ordered by the primary care team
Number of subjects: 104
Study 17624914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 1
Study 17624914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 16469079 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Number of subjects: 0
Study 16469079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid
Number of subjects: 0
Study 16469079 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid
Number of subjects: 0
Study 16469079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 0
Study 15383514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 180
Study 15383514 — intervention group
Group type: COMPARATOR
Intervention: Prudent diet (control)
Number of subjects: 180
Study 11259933 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage stimulation (HVS); 100 V, doubled‐peak monophasic impulses of 0.1 ms duration and 100 Hz frequency.
Number of subjects: 79
Study 11259933 — intervention group
Group type: COMPARATOR
Intervention: Topically applied medicine (Control group B)
Number of subjects: 79
Study 11259933 — intervention group
Group type: COMPARATOR
Intervention: Unna's boot (Control group C)
Number of subjects: 79
Study 8686328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym
Number of subjects: 30
Study 8686328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1647193 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (160 micrograms kg‐1 body weight)
Number of subjects: 12
Study 1647193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 12
Study 1647193 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron and Lorazepam (in combination)
Number of subjects: 12
Study 1647193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6856226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5% bupivacaine, dilute epinephrine, and methylergonovine maleate (randomized drug regimens)
Number of subjects: 215
Study 6856226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (nonrandomized selected group)
Number of subjects: 215
Study 30561134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 165
Study 25419583 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Tobacco Counseling (ATC)
Number of subjects: 1948
Study 25419583 — intervention group
Group type: COMPARATOR
Intervention: Tobacco-Only Counseling (TOC)
Number of subjects: 1948
Study 25419583 — intervention group
Group type: EXPERIMENTAL
Intervention: ATC
Number of subjects: 1948
Study 25419583 — intervention group
Group type: COMPARATOR
Intervention: TOC
Number of subjects: 1948
Study 23406294 — intervention group
Group type: EXPERIMENTAL
Intervention: High quantity and quality of participation
Number of subjects: 179
Study 23406294 — intervention group
Group type: COMPARATOR
Intervention: Low quantity or quality of participation
Number of subjects: 179
Study 23550422 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 216
Study 23550422 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and extended release nicotinic acid 1G
Number of subjects: 216
Study 18381377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells (BMC)
Number of subjects: 47
Study 18381377 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 47
Study 16644639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 100
Study 16644639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12792352 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to combivir (zidovudine/lamivudine) and abacavir
Number of subjects: 37
Study 12792352 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment with stavudine and/or protease inhibitor
Number of subjects: 37
Study 12792352 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to combivir/abacavir
Number of subjects: 37
Study 10857179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node dissection (SLND)
Number of subjects: 0
Study 10857179 — intervention group
Group type: COMPARATOR
Intervention: Classical lymph node dissection
Number of subjects: 0
Study 8864730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day chemoprophylaxis with clindamycin-cefonicid
Number of subjects: 162
Study 8864730 — intervention group
Group type: COMPARATOR
Intervention: 3-day chemoprophylaxis with clindamycin-cefonicid
Number of subjects: 162
Study 1515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.5 mg/kg four times daily on days 2-5 plus dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5
Number of subjects: 63
Study 1515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C
Number of subjects: 63
Study 1515247 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5
Number of subjects: 63
Study 6338767 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI plus aerochamber (AC)
Number of subjects: 12
Study 6338767 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 12
Study 6338767 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI plus AC
Number of subjects: 12
Study 30529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib + concurrent transarterial chemoembolization (cTACE)
Number of subjects: 339
Study 30529387 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 339
Study 30529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib + cTACE (≥2 sessions)
Number of subjects: 339
Study 28777900 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged compression protocol (n=50)
Number of subjects: 100
Study 28777900 — intervention group
Group type: COMPARATOR
Intervention: Linear compression protocol (n=50)
Number of subjects: 100
Study 26598748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 96
Study 26598748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 25053385 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoramide mustard (PAM) measured as N‐[2‐(2‐oxazolidonyl)ethyl]‐valyl Hb (OzVal‐Hb)
Number of subjects: 12
Study 22031509 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol measured in response to mental stressors (5-min Stroop task and 5-min mirror tracing task)
Number of subjects: 479
Study 22031509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol stress reactivity
Number of subjects: 479
Study 22031509 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measured at study entry and at 3-year follow-up
Number of subjects: 479
Study 18819705 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 746
Study 18819705 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 746
Study 18819705 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 8 mg
Number of subjects: 746
Study 17180281 — intervention group
Group type: EXPERIMENTAL
Intervention: HALO360 system with 14 J/cm2 for 4 applications
Number of subjects: 8
Study 17180281 — intervention group
Group type: EXPERIMENTAL
Intervention: HALO360 system with 12 J/cm2 for 2 applications
Number of subjects: 8
Study 17180281 — intervention group
Group type: EXPERIMENTAL
Intervention: HALO360 system with 10, 12, or 14 J/cm2 for two, three, or four applications
Number of subjects: 8
Study 15826228 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory cue matching the shape containing the target
Number of subjects: 0
Study 15826228 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory cue containing a distractor
Number of subjects: 0
Study 15826228 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid memory cue
Number of subjects: 0
Study 15826228 — intervention group
Group type: EXPERIMENTAL
Intervention: No memory cue
Number of subjects: 0
Study 15826228 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive trials with memory cues
Number of subjects: 0